Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

hem-onc-updates

Advertisement

ELZONRIS® (Tagraxofusp-erzs)

December 27, 2018May 4, 2020 RR FDA Approvals
General Medical Oncology & Hematology

The FDA on December 21, 2018 approved ELZONRISĀ®, a CD123-directed cytotoxin, for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRISĀ® is a product of Stemline Therapeutics.

Post navigation

ULTOMIRIS® (Ravulizumab-cwvz)
Baseline Corticosteroid Use at Start of PD-1/PD-L1 Inhibitor Therapy Negatively Affects Outcomes in NSCLC

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

OncoPrescribe-Ad

Advertisement

Ad 2

OncoPrescribe-CDC

Advertisement

Ad 3

OncoPrescribe-Ad

Advertisement

Ad 4

OncoPrescribe

Advertisement

  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved